^
    Back
    Association details:
    Biomarker:UGT1A1*28
    Cancer:Colorectal Cancer
    Drug:capecitabine (Thymidylate synthase inhibitor) +
    irinotecan (Topoisomerase I inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: B - Late Trials
    Source:
    J Clin Oncol
    Title:

    Multicenter, Randomized, Phase III Trial of Neoadjuvant Chemoradiation With Capecitabine and Irinotecan Guided by UGT1A1 Status in Patients With Locally Advanced Rectal Cancer

    Published date:
    10/29/2020
    Excerpt:
    ...the experimental group: radiation with capecitabine combined with weekly irinotecan 80 mg/m2 for patients with UGT1A1*1*1 or 65 mg/m2 for patients with UGT1A1*1*28, followed by irinotecan and capecitabine....The pCR rates were 15% (n = 27 of 178) and 30% (n = 53 of 178) in the control and experimental groups (risk ratio, 1.96; 95% CI, 1.30 to 2.97; P = .001)....Adding irinotecan guided by UGT1A1 genotype to capecitabine-based neoadjuvant chemoradiotherapy significantly increased complete tumor response in Chinese patients.
    DOI:
    10.1200/JCO.20.01932
    Trial ID:
    CinClare
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Go to data
    Source:
    clinicaltrials.gov
    Title:

    Trial of Capecitabine With or Without Irinotecan Driven by UGT1A1

    Excerpt:
    ...- UGT1A1*28 6/6 or 6/7...
    Trial ID:
    CinClare